State Street’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-579,404
| Closed | -$12.6M | – | 3794 |
|
|
2017
Q2 | $12.6M | Buy |
579,404
+9,450
| +2% | +$172K | ﹤0.01% | 2280 |
|
|
2017
Q1 | $8M | Buy |
569,954
+57,135
| +11% | +$936K | ﹤0.01% | 2473 |
|
|
2016
Q4 | $9.62M | Buy |
512,819
+34,448
| +7% | +$586K | ﹤0.01% | 2359 |
|
|
2016
Q3 | $7.9M | Sell |
478,371
-627
| -0.1% | -$9.29K | ﹤0.01% | 2311 |
|
|
2016
Q2 | $6.43M | Buy |
478,998
+25,915
| +6% | +$378K | ﹤0.01% | 2462 |
|
|
2016
Q1 | $6.93M | Buy |
453,083
+221
| +0% | +$3.46K | ﹤0.01% | 2378 |
|
|
2015
Q4 | $8.99M | Buy |
452,862
+9,093
| +2% | +$173K | ﹤0.01% | 2249 |
|
|
2015
Q3 | $7.73M | Buy |
443,769
+15,890
| +4% | +$324K | ﹤0.01% | 2312 |
|
|
2015
Q2 | $8.65M | Buy |
427,879
+17,283
| +4% | +$334K | ﹤0.01% | 2347 |
|
|
2015
Q1 | $7.23M | Buy |
410,596
+16,324
| +4% | +$278K | ﹤0.01% | 2380 |
|
|
2014
Q4 | $6.42M | Buy |
394,272
+3,653
| +0.9% | +$67K | ﹤0.01% | 2438 |
|
|
2014
Q3 | $8.62M | Buy |
390,619
+6,957
| +2% | +$142K | ﹤0.01% | 2264 |
|
|
2014
Q2 | $7.72M | Buy |
383,662
+40,446
| +12% | +$685K | ﹤0.01% | 2357 |
|
|
2014
Q1 | $6.38M | Buy |
343,216
+2,051
| +0.6% | +$28.2K | ﹤0.01% | 2443 |
|
|
2013
Q4 | $3.44M | Buy |
341,165
+36,904
| +12% | +$446K | ﹤0.01% | 2785 |
|
|
2013
Q3 | $3.92M | Buy |
304,261
+55,295
| +22% | +$680K | ﹤0.01% | 2662 |
|
|
2013
Q2 | $2.96M | Buy |
+248,966
| New | +$2.7M | ﹤0.01% | 2746 |
|
Other funds holding AMRI
State Street's AMRI Position: Q3 2017 in Review
State Street sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 579,404 shares — an estimated $12.6M sold.
State Street first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $12.6M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- State Street reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- State Street sold 579,404 Albany Molecular Research Inc shares in Q3 2017, an estimated $12.6M.
- State Street first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- State Street's Albany Molecular Research Inc position peaked at $12.6M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on State Street's 13F filing for Q3 2017, filed 14 Nov 2017.